Tivozanib Communications Come Back To Haunt Aveo, Former Execs
Executive Summary
Company pays $4m to settle SEC claims that it failed to publicly disclose FDA's May 2012 recommendation for a new trial of its tyrosine kinase inhibitor, the subject of a negative advisory committee review a year later. Fraud claims against three former officers continue.
You may also be interested in...
Persistence Pays Off With US Approval Of Aveo’s Fotivda In RCC
The approval marks the first commercial launch for Aveo in the US, but tivozanib has shown modest efficacy in cancer and the approval is relegated to later lines.
Clovis, CEO Mahaffy Settle SEC Investor Fraud Charges Over Rociletinib Efficacy Claims
Clovis, CEO Patrick Mahaffy and former CFO Erie Mast will pay more than $20m to settle charges by the SEC that the company misled investors on the efficacy of rociletinib. Clovis raised $298m in a public stock offering during the timeframe SEC says it misled investors.
Immuno-Oncology Outlook: Pfizer's Inlyta Fits Well In Combos For Kidney Cancer
As the RCC field braces for another paradigm change, early studies combining tyrosine kinase inhibitors with PD-1/L1 inhibitors suggest the highest response rates are found with Inlyta (axitinib) as a partner.